Company: SCLXW
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0000950170-25-071904
Chunk: 7

Company: Scilex Holding Co
Filing Date: 2025-05-15
Form: 424B3
Chunk 7
---
 |
| Payments on purchased revenue liability                                                           |                              |    (797 | ) |     |      |       — |   |
| Transaction costs paid in connection with share repurchase                                        |                              |    (396 | ) |     |      |       — |   |
| Proceeds from issuance of shares under direct offerings                                           |                              |       — |   |     |      |  10,000 |   |
| Payments of direct offering issuance costs                                                        |                              |       — |   |     |      |  (1,277 | ) |
| Excise tax paid in connection with share repurchase                                               |                              |    (200 | ) |     |      |       — |   |
| Payments of deferred transaction costs related to Semnur Business Combination                     |                              |     (95 | ) |     |      |       — |   |
| Proceeds from stock options exercised                                                             |                              |       — |   |     |      |      46 |   |
| Net cash used for financing activities                                                            |                              |  (3,084 | ) |     |      | (11,196 | ) |
| Net change in cash, cash equivalents and restricted cash                                          |                              |   2,528 |   |     |      |  (1,955 | ) |
| Cash, cash equivalents and restricted cash at beginning of period                                 |                              |   3,272 |   |     |      |   4,729 |   |
| Cash, cash equivalents and restricted cash at end of period                                       | $                            |   5,800 |   |     | $    |   2,774 |   |
| Non-cash investing and financing activities                                                       |                              |         |   |     |      |         |   |
| Issuance costs related to February 2024 BDO included in accrued expenses                          | $                            |       — |   |     | $    |   1,501 |   |

See accompanying notes to unaudited condensed consolidated financial statements.

<div align='center'>4

SCILEX HOLDING COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)</div>

1. Nature of Operations and Basis of Presentation

Organization and Principal Activities

Scilex Holding Company (“Scilex” and together with its wholly owned subsidiaries, the “Company”) is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products